BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen Y, Tian Z. HBV-Induced Immune Imbalance in the Development of HCC. Front Immunol 2019;10:2048. [PMID: 31507621 DOI: 10.3389/fimmu.2019.02048] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang M, Zhao H, Gao H. Interleukin-24 Limits Tumor-Infiltrating T Helper 17 Cell Response in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Viral Immunology. [DOI: 10.1089/vim.2021.0174] [Reference Citation Analysis]
2 Medhat A, Arzumanyan A, Feitelson MA. Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma. Oncotarget 2021;12:2421-33. [PMID: 34853663 DOI: 10.18632/oncotarget.28077] [Reference Citation Analysis]
3 Borgia M, Dal Bo M, Toffoli G. Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4387. [PMID: 34503196 DOI: 10.3390/cancers13174387] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lou Z, Zhou R, Su Y, Liu C, Ruan W, Jeon CO, Han X, Lin C, Jia B. Minor and major circRNAs in virus and host genomes. J Microbiol 2021;59:324-31. [DOI: 10.1007/s12275-021-1021-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhao L, Jin Y, Yang C, Li C. HBV-specific CD8 T cells present higher TNF-α expression but lower cytotoxicity in hepatocellular carcinoma. Clin Exp Immunol 2020;201:289-96. [PMID: 32474905 DOI: 10.1111/cei.13470] [Reference Citation Analysis]
6 He T, Zhang N, Wang L, Wan B, Wang X, Zhang L. GPR43 regulates HBV X protein (HBx)-induced inflammatory response in human LO2 hepatocytes. Biomedicine & Pharmacotherapy 2020;123:109737. [DOI: 10.1016/j.biopha.2019.109737] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Zhao Y, Kong LX, Feng FS, Yang J, Wei G. A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study. BMC Cancer 2022;22:311. [PMID: 35321670 DOI: 10.1186/s12885-022-09433-3] [Reference Citation Analysis]
8 Ren L, Chen D, Xu W, Xu T, Wei R, Suo L, Huang Y, Chen H, Liao W. Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection. BMC Cancer 2021;21:817. [PMID: 34266388 DOI: 10.1186/s12885-021-08565-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhou J, Wang FD, Wang ML, Tao YC, Wu DB, Sheng YJ, Xiao GB, Chen XB, Chen X, Chen EQ. Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus. Front Med (Lausanne) 2021;8:717125. [PMID: 34527683 DOI: 10.3389/fmed.2021.717125] [Reference Citation Analysis]
10 Shi Y, Du L, Lv D, Li Y, Zhang Z, Huang X, Tang H. Emerging role and therapeutic application of exosome in hepatitis virus infection and associated diseases. J Gastroenterol 2021;56:336-49. [PMID: 33665710 DOI: 10.1007/s00535-021-01765-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Hu G, Huang MX, Li WY, Gan CJ, Dong WX, Peng XM. Liver damage favors the eliminations of HBV integration and clonal hepatocytes in chronic hepatitis B. Hepatol Int 2021;15:60-70. [PMID: 33534083 DOI: 10.1007/s12072-020-10125-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sun YD, Zhang H, Chen YQ, Wu CX, Chen ML, Xu HR, Wang S, Liu JZ, Han JJ. Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1. BMC Cancer 2021;21:1063. [PMID: 34583662 DOI: 10.1186/s12885-021-08783-8] [Reference Citation Analysis]
13 Chen S, Ma W, Shen L, Wu Y, Qi H, Cao F, Huang T, Fan W. Recurrence Beyond the Milan Criteria of HBV-Related Single Hepatocellular Carcinoma of 2-3 cm: Comparison of Resection and Ablation. Front Oncol 2021;11:757149. [PMID: 34733791 DOI: 10.3389/fonc.2021.757149] [Reference Citation Analysis]
14 Akbar SMF, Al Mahtab M, Cesar Aguilar J, Uddin MH, Khan MSI, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical. Exploration of Medicine. [DOI: 10.37349/emed.2021.00058] [Reference Citation Analysis]
15 Ghosh S, Chakraborty A, Banerjee S. Persistence of Hepatitis B Virus Infection: A Multi-Faceted Player for Hepatocarcinogenesis. Front Microbiol 2021;12:678537. [PMID: 34526974 DOI: 10.3389/fmicb.2021.678537] [Reference Citation Analysis]
16 Liu Z, Wang J, Liu L, Yuan H, Bu Y, Feng J, Liu Y, Yang G, Zhao M, Yuan Y, Zhang H, Yun H, Zhang X. Chronic ethanol consumption and HBV induce abnormal lipid metabolism through HBx/SWELL1/arachidonic acid signaling and activate Tregs in HBV-Tg mice. Theranostics 2020;10:9249-67. [PMID: 32802190 DOI: 10.7150/thno.46005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Qin SK, Li Q, Ming Xu J, Liang J, Cheng Y, Fan Y, Jiang J, Ye H, Tao H, Li L, Zheng L, Wei Z, Li S, Meng K, Ye B, Sun Y. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. Cancer Sci. 2020;111:4218-4231. [PMID: 32889778 DOI: 10.1111/cas.14641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Song W, Zhang X, Feng L, Lai Y, Li T, Zhang P. Downregulated lncRNA SNHG18 Suppresses the Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma and Meditates the Antitumor Effect of Oleanolic Acid. CMAR 2022;Volume 14:687-95. [DOI: 10.2147/cmar.s346920] [Reference Citation Analysis]
19 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Zhang B, Liu Z, Cao K, Shan W, Liu J, Wen Q, Wang R. Circ-SPECC1 modulates TGFβ2 and autophagy under oxidative stress by sponging miR-33a to promote hepatocellular carcinoma tumorigenesis. Cancer Med 2020;9:5999-6008. [PMID: 32627938 DOI: 10.1002/cam4.3219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
22 Kishta S, Tabll A, Omanovic Kolaric T, Smolic R, Smolic M. Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals. Biomedicines 2020;8:E175. [PMID: 32630610 DOI: 10.3390/biomedicines8060175] [Reference Citation Analysis]
23 Liu T, Li W, Zhang Y, Siyin ST, Zhang Q, Song M, Zhang K, Liu S, Shi H. Associations between hepatitis B virus infection and risk of colorectal Cancer: a population-based prospective study. BMC Cancer 2021;21:1119. [PMID: 34663268 DOI: 10.1186/s12885-021-08846-w] [Reference Citation Analysis]
24 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wang X, Liu Y, Lu Y, Chen S, Xing Y, Yang H, Wang X, Zhang Y, Pan T, Li J, Wang M, Zhang N, Liang M, Zhou F. Clinical impact of Fn-induced high expression of KIR2DL1 in CD8 T lymphocytes in oesophageal squamous cell carcinoma. Ann Med 2022;54:51-62. [PMID: 34935568 DOI: 10.1080/07853890.2021.2016942] [Reference Citation Analysis]
26 Chuang Y, Tsai K, Ou JJ. Pathogenicity and virulence of Hepatitis B virus. Virulence 2022;13:258-96. [DOI: 10.1080/21505594.2022.2028483] [Reference Citation Analysis]
27 Ma L, Sun X, Kong X, Gao Y. B cell dysfunction in chronic hepatitis B virus infection. Liver Research 2021;5:11-5. [DOI: 10.1016/j.livres.2020.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ouyang M, Yu C, Deng X, Zhang Y, Zhang X, Duan F. O-GlcNAcylation and Its Role in Cancer-Associated Inflammation. Front Immunol 2022;13:861559. [DOI: 10.3389/fimmu.2022.861559] [Reference Citation Analysis]
29 Wang C, Lv Y, Sha Z, Zhang J, Wu J, Qi Y, Guo Z. Dicer Enhances Bevacizumab-Related Inhibition of Hepatocellular Carcinoma via Blocking the Vascular Endothelial Growth Factor Pathway. J Hepatocell Carcinoma 2021;8:1643-53. [PMID: 35004391 DOI: 10.2147/JHC.S327258] [Reference Citation Analysis]
30 Zhang Y, Wang F, Wang Y. LncRNA TSPEAR-AS1 predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma and promotes metastasis via miR-1915-5p. Virus Res 2022;:198788. [PMID: 35477008 DOI: 10.1016/j.virusres.2022.198788] [Reference Citation Analysis]
31 Qiu H, Wang N, Lin D, Yuan Y, Li J, Mao D, Meng Y. The positive feedback loop of furin and TGFβ1 enhances the immune responses of Tregs to hepatocellular carcinoma cells and hepatitis B virus in vitro. Cell Biol Int 2022. [PMID: 35349767 DOI: 10.1002/cbin.11806] [Reference Citation Analysis]
32 Zhou Q, Zhang Q, Wang K, Huang T, Deng S, Wang Y, Cheng C. Anti-rheumatic Drug-induced Hepatitis B Virus Reactivation and Preventive Strategies for Hepatocellular Carcinoma. Pharmacol Res 2022;:106181. [PMID: 35301112 DOI: 10.1016/j.phrs.2022.106181] [Reference Citation Analysis]
33 Cho HJ, Cheong JY. Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Int J Mol Sci 2021;22:8011. [PMID: 34360777 DOI: 10.3390/ijms22158011] [Reference Citation Analysis]
34 Chen W, Desert R, Ge X, Han H, Song Z, Das S, Athavale D, You H, Nieto N. The Matrisome Genes From Hepatitis B-Related Hepatocellular Carcinoma Unveiled. Hepatol Commun 2021;5:1571-85. [PMID: 34510837 DOI: 10.1002/hep4.1741] [Reference Citation Analysis]
35 Huang M, Zhang W, Chen H, Zeng J. Targeting Polyamine Metabolism for Control of Human Viral Diseases. Infect Drug Resist 2020;13:4335-46. [PMID: 33293837 DOI: 10.2147/IDR.S262024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Wang X, Liu X, Wang P, Yu L, Yan F, Yan H, Zhou D, Yang Z. Antiviral Therapy Reduces Mortality in Hepatocellular Carcinoma Patients with Low-Level Hepatitis B Viremia. J Hepatocell Carcinoma 2021;8:1253-67. [PMID: 34708007 DOI: 10.2147/JHC.S330301] [Reference Citation Analysis]
37 Li B, Yan C, Zhu J, Chen X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Jiang W, Fang W. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. Front Immunol 2020;11:1037. [PMID: 32547550 DOI: 10.3389/fimmu.2020.01037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
38 Hirschenberger M, Hunszinger V, Sparrer KMJ. Implications of Innate Immunity in Post-Acute Sequelae of Non-Persistent Viral Infections. Cells 2021;10:2134. [PMID: 34440903 DOI: 10.3390/cells10082134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Lou W, Wang W, Chen J, Wang S, Huang Y. ncRNAs-mediated high expression of SEMA3F correlates with poor prognosis and tumor immune infiltration of hepatocellular carcinoma. Mol Ther Nucleic Acids 2021;24:845-55. [PMID: 34026328 DOI: 10.1016/j.omtn.2021.03.014] [Reference Citation Analysis]
40 Gogoi D, Borkakoty B, Biswas D, Yadav K, Patel V. Characteristics of Circulatory γδ T cells in Patients with Symptomatic Chronic Hepatitis B Infection. Viral Immunol 2021. [PMID: 34096794 DOI: 10.1089/vim.2020.0314] [Reference Citation Analysis]
41 Sun J, Cheng N, Wang F. Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-10. [DOI: 10.1155/2022/1688460] [Reference Citation Analysis]
42 Jin X, Yan ZH, Lu L, Lu S, Zhang G, Lin W. Peripheral Immune Cells Exhaustion and Functional Impairment in Patients With Chronic Hepatitis B. Front Med (Lausanne) 2021;8:759292. [PMID: 34782855 DOI: 10.3389/fmed.2021.759292] [Reference Citation Analysis]
43 Li B, Li Y, Li S, Li H, Liu L, Xu Y. Inhibition of Protease Activated Receptor 2 Attenuates HBx-Induced Inflammation and Mitochondria Oxidative Stress. IDR 2022;Volume 15:961-73. [DOI: 10.2147/idr.s343864] [Reference Citation Analysis]
44 Gu S, Liu Z, Lin L, Zhong S, Ma Y, Li X, Ye G, Wen C, Li Y, Tang L. Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array. Front Immunol 2021;12:767000. [PMID: 34721439 DOI: 10.3389/fimmu.2021.767000] [Reference Citation Analysis]
45 Chen Y, Tian Z. Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer. Cell Mol Immunol 2021;18:57-72. [PMID: 33041339 DOI: 10.1038/s41423-020-00561-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
46 Liu G, Wu D, Wen Y, Cang S. Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma: an integrated analysis of GEO datasets. Bioengineered 2021;12:5253-65. [PMID: 34424809 DOI: 10.1080/21655979.2021.1962147] [Reference Citation Analysis]
47 Chen Z, Chen Y, Peng L, Wang X, Tang N. 2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1. J Immunother Cancer 2020;8:e001377. [PMID: 33028694 DOI: 10.1136/jitc-2020-001377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
48 Lee AR, Park YK, Dezhbord M, Kim K. Interaction between the Hepatitis B Virus and Cellular FLIP Variants in Viral Replication and the Innate Immune System. Viruses 2022;14:373. [DOI: 10.3390/v14020373] [Reference Citation Analysis]
49 Khanam A, Chua JV, Kottilil S. Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. Int J Mol Sci 2021;22:5497. [PMID: 34071064 DOI: 10.3390/ijms22115497] [Reference Citation Analysis]
50 Han N, Yan L, Wang X, Sun X, Huang F, Tang H. An updated literature review: how HBV X protein regulates the propagation of the HBV. Future Virology 2020;15:649-58. [DOI: 10.2217/fvl-2020-0251] [Reference Citation Analysis]
51 Lim HK, Jeffrey GP, Ramm GA, Soekmadji C. Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles. Front Cell Infect Microbiol 2020;10:587628. [PMID: 33240824 DOI: 10.3389/fcimb.2020.587628] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Kim S, Lee Y, Bang SM, Bak H, Yim SY, Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, Um SH, Byun KS, Yeon JE. Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. J Clin Med 2021;10:1840. [PMID: 33922708 DOI: 10.3390/jcm10091840] [Reference Citation Analysis]
53 Wang Z, Duan Y, Zhang J, Lv Y, Wu S, Cheng M, Bhagavathula AS, Aldhaleei WA, Clark C, Huo Z. Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma: A meta-analysis. Eur J Pharmacol 2020;883:173382. [PMID: 32693099 DOI: 10.1016/j.ejphar.2020.173382] [Reference Citation Analysis]
54 Chen W, Zhang X, Bi K, Zhou H, Xu J, Dai Y, Diao H. Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance. Front Oncol 2020;10:554165. [PMID: 33072579 DOI: 10.3389/fonc.2020.554165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
55 Jia L, Gao Y, He Y, Hooper JD, Yang P. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res. 2020;159:104992. [PMID: 32505833 DOI: 10.1016/j.phrs.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
56 Liu Y, Veeraraghavan V, Pinkerton M, Fu J, Douglas MW, George J, Tu T. Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Front Microbiol 2021;12:665201. [PMID: 34194408 DOI: 10.3389/fmicb.2021.665201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Kawanaka M, Nishino K, Kawamoto H, Haruma K. Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases. World J Gastroenterol 2021; 27(43): 7497-7508 [PMID: 34887645 DOI: 10.3748/wjg.v27.i43.7497] [Reference Citation Analysis]
58 Han JJ, Chen Y, Nan YC, Yang YL. Extremely high titer of hepatitis B surface antigen antibodies in a primary hepatocellular carcinoma patient: A case report. World J Clin Cases 2021; 9(28): 8492-8497 [PMID: 34754858 DOI: 10.12998/wjcc.v9.i28.8492] [Reference Citation Analysis]
59 Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J. Employing hypoxia characterization to predict tumour immune microenvironment, treatment sensitivity and prognosis in hepatocellular carcinoma. Comput Struct Biotechnol J 2021;19:2775-89. [PMID: 34093992 DOI: 10.1016/j.csbj.2021.03.033] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Kong J, Liang X, Zhang J, Zeng J, Liu J, Zeng J. Antiviral Therapy Improves Survival in Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis. Dig Dis Sci 2021. [PMID: 34523084 DOI: 10.1007/s10620-021-07248-z] [Reference Citation Analysis]
61 Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021;6:263. [PMID: 34248142 DOI: 10.1038/s41392-021-00658-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]